Almil OTC Drug Manufacturing, Labeling Deficiencies Cited By FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA identifies several "serious deviations" from good manufacturing practices in a Feb. 2 warning letter to OTC drug producer Almil Nutritional Products
You may also be interested in...
Topical product manufacturers receive one-third of FDA warning letters in FY 1996.
TOPICAL PRODUCT MANUFACTURERS RECEIVED ONE-THIRD OF FY 1996 WARNING LETTERS from FDA for the year ended Sept. 30. Manufacturers of topical drugs were the recipients of 20 of the 59 warning letters issued by FDA during the fiscal year. Stability testing programs were a focal point of FDA concern; deficiencies in the stability area were addressed in more than two-thirds of the warning letters issued to topical manufacturing facilities.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands